EXORPHIA, INC.
About
EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.
Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.
Our lead pipeline comprises three pillars:
(1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)
(2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)
(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).
Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.
Business Domain / 分野
Business Type / 業種
Disease Area/疾患領域
Technologies / 技術
Additional Information
Requested business parter / ご希望のビジネスパートナー
Representatives
Head of Business Develpemt
EXORPHIA, INC.